-
-
-
-
BAFF-R CAR-T: CR 100%
CAR-T
PeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
-
-
Stylus Medicine Raises $85 Million!
Eli Lilly
Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
-
-
2024 Global CAR-T Sales Performance
CAR-T
Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
-
In Vivo CAR-T: A New Horizon
CAR-T
Explore the promising future of in vivo CAR-T therapy, a breakthrough in cancer and autoimmune disease treatment. Companies like Interius and Umoja are leading the way with innovative in vivo CAR-T therapies targeting CD19, CD20, and CD22. Discover the latest advances and clinical trials.
绩溪县|
文昌市|
湟中县|
汉中市|
嵩明县|
延吉市|
琼结县|
宜阳县|
康马县|
宁海县|
什邡市|
科技|
宁化县|
会东县|
长子县|
江油市|
高雄县|
东阳市|
揭西县|
波密县|
五常市|
清徐县|
岳池县|
阿合奇县|
辉南县|
青州市|
榕江县|
阿克苏市|
通州市|
襄樊市|
凤冈县|
万宁市|
大方县|
织金县|
左贡县|
祥云县|
庄浪县|
阿瓦提县|
阳泉市|
循化|
毕节市|